Clinical Trial Update: An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. [Phase 3]

View source ↗

Summary

A completed Phase 3 open-label extended protocol evaluating the safety and efficacy of ranibizumab in rare VEGF-driven ocular diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetic Retinopathy
• Glaucoma Neovascular
• Macular Edema

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Choroidal Neovascularization, Macular Edema | Phase 3 | Status: COMPLETED | Results posted: 2019-08-12